AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02545959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab IV
Description: Blood infusion of rituximab (375mg/m2)
Study NCT00745862 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
Description: This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
Study NCT05498129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School meal
Description: School lunch was comprised of rice, ghee and beef
Study NCT05498129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School meal plus micronutrient powder
Description: School lunch plus micronutrient powder
Study NCT05498129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No school meal
Description: No school meal
Study NCT01120184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
Study NCT01120184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 intravenously weekly for a minimum of 18 weeks
Study NCT04575467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514
Description: CBL-514 will be administered via injection into the subcutaneous adipose layer.
Study NCT03085810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
Study NCT03085810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
Study NCT03297268 — intervention group
Intervention type: OTHER
Intervention: Intervention with Home-Based Caregivers
Description: We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
Study NCT02159833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intranasal challenge with active substance (food protein)
Study NCT01621321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
Study NCT01621321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
Study NCT02510404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mCTLs
Description: The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
Study NCT03868930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-Home
Description: This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
Study NCT02159833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intranasal challenge with placebo
Study NCT03868930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCGT
Description: The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
Study NCT01381822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
Study NCT00665522 — intervention group
Intervention type: DRUG
Intervention: fentanyl iontophoretic transdermal system (40mcg) No Placebo
Description: 40 mcg per dose, maximum of 6 doses/hour
Study NCT00665522 — intervention group
Intervention type: DRUG
Intervention: IV PCA with standard of care opioid analgesia
Description: total maximum 80 doses/24 hours
Study NCT03740100 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bimiralisib
Description: Bimiralisib capsules
Study NCT03120702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Rainbow SpHb sensor
Description: Investigational Rainbow SpHb sensor
Study NCT02340156 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-53
Description: SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
Study NCT02340156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
Study NCT04119583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-shape Automatic Electric Toothbrush
Description: The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
Study NCT04119583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual home toothbrushing procedure
Description: Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
Study NCT04119583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Electric Toothbrush
Description: The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
Study NCT03603236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: preeclampsia
Description: liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
Study NCT01120184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: 840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
Study NCT01120184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab-placebo
Description: 840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
Study NCT01120184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: trastuzumab \[Herceptin\] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
Study NCT01120184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: 3.6 mg/kg intravenously every 3 weeks
Study NCT01401361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Arm
Description: The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
Study NCT02099786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMP-VA
Description: Hearing testing at each treatment interval by the comp-va audiologist
Study NCT03603236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: control
Description: liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
Study NCT01430182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: 0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
Study NCT01430182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
Study NCT02447510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: group 1 bio-oss bone xenograft
Description: bone substitute (bio-oss)
Study NCT02447510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)
Description: platelet rich in growth factor (autogenous platelet rich in growth factor)
Study NCT02447510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: group 3 platelet rich fibrin (autogenous platelet rich fibrin)
Description: platelet rich fibrin (autogenous platelet rich fibrin)
Study NCT02099786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Hearing testing done in the audiology clinic after oncology referral or patient self referral
Study NCT02006589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (GW615775, Test formulation)
Description: Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
Study NCT02006589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Reference treatment)
Description: Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
Study NCT01506115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin
Description: Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
Study NCT02324985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ibuprofen Topical Gel 5%
Description: S-Ibuprofen Topical Gel 5% applied every 6 hours
Study NCT02324985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: Vehicle Topical Gel applied every 6 hours
Study NCT03782649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Working Model 3.4NR
Description: Investigational Medical Device collecting spectral Raman data from tissue
Study NCT03953365 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prophylactic Mesh
Description: Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Study NCT03774979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
Study NCT03845478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: The control group is subjected to follow a hypocaloric diet and receives information about the benefits of achieving 10,000 steps a day in weight loss and improved body composition.
Study NCT03845478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: This group in addition to fulfilling a hypocaloric diet identical to the control group, and receive identical information about physical activity that the control group, it has a system of prescription, monitoring and establishing an objective to achieve 10,000 steps a day.
Study NCT00739661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg
Description: Vismodegib 150 mg was provided in hard gelatin capsules.
Study NCT00739661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to vismodegib
Description: Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
Study NCT00510211 — intervention group
Intervention type: DRUG
Intervention: olanzapine
Study NCT03534141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal cooling/warming device
Description: The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
Study NCT03534141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal cooling/warming device
Description: The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
Study NCT03534141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Description: Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
Study NCT03534141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
Study NCT01510665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium citrate
Description: Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
Study NCT01510665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo with inactive ingredients, two pills once daily.
Study NCT01510665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary modification
Description: Nutritionist counseling session and advice on following a magnesium rich diet
Study NCT01714505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs)
Description: A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
Study NCT01563042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) single dose
Description: GSK2434735 administered as a single intervenous dose at the beginning of the study
Study NCT01563042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) single dose
Description: GSK2434735 administered as a single subcutaneous dose at the beginning of the study
Study NCT02591160 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HCTZ cessation
Description: Patients will stop taking their HCTZ for 3 months
Study NCT01506037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine ODT 5 mg
Study NCT01506037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine ODT 5 mg
Study NCT02957253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: risk factors
Description: monitoring risk factors due to deterioration of the liver disease
Study NCT02957253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-care
Description: information and motivation to adherence to self-care instructions and medical treatment
Study NCT01856127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
Study NCT02957253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition
Description: nutritional assessment and activities to prevent malnutrition
Study NCT02957253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle
Description: motivation of lifestyle changes essential for disease progress and
Study NCT02957253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial needs
Description: psychosocial care.
Study NCT02957253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Description: compensated disease once yearly, decompensated disease twice a month to every third month
Study NCT04232488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography using distal radial artery
Description: Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
Study NCT04232488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography using proximal radial artery
Description: Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
Study NCT00508014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care with primary care provider during time period
Study NCT00508014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Peer Review visit
Description: Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
Study NCT04028050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks.
Study NCT04028050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing) with standard anti-emetics per local practice guidelines.
Study NCT04028050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered by IV infusion over 60 minutes following carboplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.